TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03697434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care referral
Description: Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
Study: NCT03156127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-UPS 5 mg tablet, Inisia 5 mg tablet
Description: Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR-UPS 5 mg tablet, Inisia 5 mg tablet
Description: Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
Study: NCT05298982

Intervention type: BEHAVIORAL
Intervention: Early activity and Mobilisation Intervention
Description: The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
Study: NCT00617604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: IV and subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV and subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus
Description: The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolic mofetil was administered as 750 mg twice per day orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolic mofetil was administered as 750 mg twice per day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroids
Description: Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally
Study: NCT00154336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imatinib Placebo
Study: NCT00786812

Intervention type: DRUG
Group type: OTHER
Intervention: Nilotinib

Intervention type: DRUG
Group type: OTHER
Intervention: Nilotinib
Study: NCT00420602

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Over the counter DHA/EPA dietary supplementation
Description: 1000 mg/day DHA/EPA
Study: NCT01193881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03672578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icon
Description: label with icon and text

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icon
Description: label with icon and text

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icon
Description: label with icon and text
Study: NCT01193881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02530983

Intervention type: OTHER
Intervention: Mayo Clinic Upper Digestive Disease Survey on Paper
Description: Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.

Intervention type: OTHER
Intervention: Mayo Clinic Upper Digestive Disease Survey on Paper
Description: Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.

Intervention type: OTHER
Intervention: Upper Digestive Disease (UDD Monitor) App
Description: Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile\&pli=1

Intervention type: OTHER
Intervention: Upper Digestive Disease (UDD Monitor) App
Description: Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile\&pli=1
Study: NCT02627755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aScope®
Description: we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope®
Description: use of Glidescope® in conventional manner to facilitate endotracheal intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope®
Description: use of Glidescope® in conventional manner to facilitate endotracheal intubation
Study: NCT01854645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI
Description: GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI
Description: GP MDI administered as two puffs BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI
Description: FF MDI administered as two puffs BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
Description: Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Inhaled placebo administered as two puffs BID
Study: NCT02326714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo auricular acupressure
Description: The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
Study: NCT01223521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate intrauterine contraception
Description: A Cu-IUD or LNG-IUS is inserted after abortion.
Study: NCT03050996

Intervention type: PROCEDURE
Intervention: robotic radical prostatectomy
Description: Urodynamic evaluation during robotic radical prostatectomy
Study: NCT02075411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous perineural infusion catheter
Description: Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous perineural infusion catheter
Description: Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
Study: NCT03178968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: 3 immersion times in orange juice were investigated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: 3 immersion times in orange juice were investigated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: 3 immersion times in orange juice were investigated
Study: NCT04687761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib 40 mg/daily oral, days, 8 to 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib 40 mg/daily oral, days 8 to 28
Study: NCT03533595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Barbed
Description: Barbed Suture
Study: NCT01109836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation and lifestyle intervention
Description: Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
Study: NCT03671746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Participants will receive Ketorolac at 30 mg IV every 6 hours for their first 5 days of hospitalization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Participants will receive 10 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
Study: NCT00824824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 2%-timolol 0.5%
Description: BID OU for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%-0.5% timolol 0.5
Description: BID OU for 6 weeks
Study: NCT00979251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate
Description: Oseltamivir Phosphate, q8h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-8902
Description: Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
Study: NCT02717754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oseltamivir matched placebo will be administered intravenous for 5 days.
Study: NCT03430219

Intervention type: DEVICE
Intervention: Subchondroplasty Procedure
Description: AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
Study: NCT00617539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT03666000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azer-cel
Description: Infusion of Allogeneic Anti-CD19 CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azer-cel
Description: Infusion of Allogeneic Anti-CD19 CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azer-cel
Description: Infusion of Allogeneic Anti-CD19 CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azer-cel
Description: Infusion of Allogeneic Anti-CD19 CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azer-cel
Description: Infusion of Allogeneic Anti-CD19 CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azer-cel
Description: Infusion of Allogeneic Anti-CD19 CAR T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Specified dose on specified days
Study: NCT03952338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food coupons
Description: Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition skill-building
Description: Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
Study: NCT04555837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03691935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
Study: NCT01789099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1 synthetic peptide vaccine and GM-CSF
Study: NCT02294435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visceral Manifold and Thoracic Bifurcation
Description: Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visceral Manifold and Thoracic Bifurcation
Description: Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unitary Manifold
Description: Unitary Manifold Endovascular stent graft system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unitary Manifold
Description: Unitary Manifold Endovascular stent graft system
Study: NCT04605445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 visit root canal treatment (endodontics)
Description: Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 visits root canal treatment (endodontics)
Description: Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
Study: NCT04662619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B. infantis
Description: Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU), will be provided to infants once daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Placebo
Description: Powdered infant formula grade lactose will be provided to infants once daily for 12 weeks.
Study: NCT03370848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325 mg tablet 30 minutes prior to niacin ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 325 mg tablet 30 minutes prior to niacin ER
Study: NCT02509897

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxic training
Description: Hypoxic training 3 times per week four four weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoxic training
Description: Normoxic training 3 times per week four four weeks
Study: NCT00794443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM529 / ONO-5920
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM529 / ONO-5920
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YM529 / ONO-5920
Description: Oral
Study: NCT00823303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 1 mcg daily, adjusted to achieve 40-60% PTH suppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: 0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
Study: NCT01320787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoroacetate
Description: 18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
Study: NCT01028456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: 10,000 lux / 30 minutes a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 100 lux
Description: Placebo light